EUVIMEDDescoperă EUVIMED
Open access

Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy

Li Lin

Clinical medicine. Pathology · 2008

DOI: 10.4137/cpath.s667 ↗

At a glance

Journal article in Clinical medicine. Pathology, 2008. Written by Li Lin. Institution: Key laboratory of cellular physiology, Shanxi Medical University, China. Cited 9 times so far (Crossref); 97 references. The full text is freely available in PubMed Central.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

A surprising common pathological processes is found between Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM)[1]. AD and T2DM share some common pathological processes: Amyloid β (Aβ), τ hyperphosphoralation, insulin abnormality. Disturbance in insulin signalling is not only involved in blood glucose level but also in numerous degenerative processes. Glucagon-like peptide 1 (GLP-1) has attracted substantial attention for its advantage in treating T2DM. GLP-1 can reduce Aβ levels in brain. All these encourage us in a medical hypothesis: that is, that GLP-1 is a promising agent in the therapy of AD.

Subjects

Author keywords

Alzheimer’s diseasediabetesglucagon-like peptide 1

Authors and institutions

  • Key laboratory of cellular physiology, Shanxi Medical University, China.

Cite

APA

Lin, L. (2008). Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy. Clinical medicine. Pathology. https://doi.org/10.4137/cpath.s667

Vancouver

Lin L. Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy. Clinical medicine. Pathology. 2008. doi:10.4137/cpath.s667

BibTeX
@article{Lin2008,
  author = {Lin, Li},
  title = {Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy},
  journal = {Clinical medicine. Pathology},
  year = {2008},
  doi = {10.4137/cpath.s667}
}
Start for free →